- Home
- GNFT vs PRME Comparison
GNFT vs PRME Comparison
Compare GNFT & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- PRME
- Stock Information
- Founded
- GNFT 1999
- PRME 2019
- Country
- GNFT France
- PRME United States
- Employees
- GNFT N/A
- PRME N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- PRME Medicinal Chemicals and Botanical Products
- Sector
- GNFT Health Care
- PRME Health Care
- Exchange
- GNFT Nasdaq
- PRME Nasdaq
- Market Cap
- GNFT 186.3M
- PRME 191.7M
- IPO Year
- GNFT 2019
- PRME 2022
- Fundamental
- Price
- GNFT $4.14
- PRME $4.21
- Analyst Decision
- GNFT Strong Buy
- PRME Buy
- Analyst Count
- GNFT 1
- PRME 6
- Target Price
- GNFT $13.00
- PRME $9.38
- AVG Volume (30 Days)
- GNFT 4.0K
- PRME 5.8M
- Earning Date
- GNFT 09-18-2025
- PRME 08-04-2025
- Dividend Yield
- GNFT N/A
- PRME N/A
- EPS Growth
- GNFT N/A
- PRME N/A
- EPS
- GNFT 0.03
- PRME N/A
- Revenue
- GNFT $73,187,701.00
- PRME $3,846,000.00
- Revenue This Year
- GNFT $15.98
- PRME $104.12
- Revenue Next Year
- GNFT N/A
- PRME $108.24
- P/E Ratio
- GNFT $132.83
- PRME N/A
- Revenue Growth
- GNFT 105.01
- PRME 550.76
- 52 Week Low
- GNFT $2.55
- PRME $1.11
- 52 Week High
- GNFT $6.42
- PRME $5.95
- Technical
- Relative Strength Index (RSI)
- GNFT 58.36
- PRME 60.42
- Support Level
- GNFT $3.94
- PRME $3.71
- Resistance Level
- GNFT $4.20
- PRME $5.15
- Average True Range (ATR)
- GNFT 0.13
- PRME 0.53
- MACD
- GNFT 0.05
- PRME -0.06
- Stochastic Oscillator
- GNFT 91.62
- PRME 34.25
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.